Absence of glaucoma in DBA/2J mice homozygous for wild-type versions of Gpnmb and Tyrp1
© Howell et al; licensee BioMed Central Ltd. 2007
Received: 09 January 2007
Accepted: 03 July 2007
Published: 03 July 2007
The glaucomas are a common but incompletely understood group of diseases. DBA/2J mice develop a pigment liberating iris disease that ultimately causes elevated intraocular pressure (IOP) and glaucoma. We have shown previously that mutations in two genes, Gpnmb and Tyrp1, initiate the iris disease. However, mechanisms involved in the subsequent IOP elevation and optic nerve degeneration remain unclear.
Here we present new mouse strains with Gpnmb and/or Tyrp1 genes of normal function and with a DBA/2J genetic background. These strains do not develop elevated IOP or glaucoma with age.
These strains provide much needed controls for studying pathogenic mechanisms of glaucoma using DBA/2J mice. Given the involvement of Gpnmb and/or Tyrp1 in areas such as immunology and tumor development and progression, these strains are also important in other research fields.
Glaucomas are heterogeneous diseases that affect 70 million people worldwide . They are characterized by the loss of retinal ganglion cells and degeneration of the optic nerve [2, 3]. Glaucoma is often associated with an age-related elevation of intraocular pressure (IOP) . Elevated IOP induces glaucomatous neurodegeneration in susceptible individuals. IOP elevation involves compromised drainage of aqueous humor (AqH) through the ocular drainage structures in the iridocorneal angle (angle) . Nevertheless, the molecular etiology of IOP elevation varies between individuals and with the type of glaucoma. In pigmentary glaucoma, the iris is damaged resulting in dispersal of iris pigment and debris into the anterior chamber and AqH drainage structures. In susceptible individuals, the pigment and/or debris induces a process(es) that damages the drainage structures resulting in high IOP and subsequent glaucoma [6–8]. DBA/2J (D2) mice inherit a disease with similarities to human pigmentary glaucoma [9, 10], including ultrastructurally abnormal melanosomes . Around 5–6 months of age, D2 mice develop a pigment dispersing iris disease. Pigment and/or iris debris induces drainage structure damage that disrupts the outflow of aqueous humor. This causes an elevation of IOP that first occurs in a significant portion of mice around 8–9 months of age . In our colony, about 70% of D2 mice develop moderate or severe glaucoma by 12 months of age . There are now a number of independent reports on DBA/2 glaucoma including several recent ones (e.g. [10, 12–14]). Some but not all of these reports suggest earlier onset damage than we have reported. This earlier onset damage clearly does not occur in our colony as we have studied large numbers of mice . We have previously discussed possible explanations for these differences including the exact substrain used and environmental differences.
We have previously shown that the D2 iris disease is genetically separable into two distinct traits, iris pigment dispersion (IPD) and iris stromal atrophy (ISA) . IPD is characterized by a breakdown of the posterior iris pigment epithelium, slit-like transillumination and prominent pigment dispersion. IPD is caused by a mutation in the glycoprotein (transmembrane) nmb gene (Gpnmb R150X ), a recent mutation that arose on D2 in the early 1980's [10, 16]. ISA is characterized by deterioration of the iris stroma, and an accumulation of stromal pigment and cell debris in the drainage structures , and is caused by a recessive mutation in the tyrosinase related protein 1 gene (Tyrp1 b ) . D2 mice are homozygous for both Gpnmb R150X and Tyrp1b mutations and inherit a much more severe iris disease and subsequent glaucoma than mice carrying either of the two mutations alone . The published characterization of both IPD and ISA was necessarily performed using mice of a mixed genetic background when mapping and identifying the genes that underlie these traits. These phenotypes have never been fully analyzed in the context of a D2 genetic background.
D2 is one of the most widely used mouse strains in glaucoma research. Here, we describe the development of novel strains that can be used in conjunction with D2 to further our understanding of the complex mechanisms involved in pigment dispersing iris disease, IOP elevation and glaucoma. Prior to developing these strains, there were no control, age and strain-matched DBA/2J mice that did not develop these phenotypes. Control D2.B6-Tyrp1 B6 Gpnmb B6 /Sj mice (hereafter referred to as D2.Tyrp1 B6 Gpnmb B6 ) are homozygous for wild type alleles of Tyrp1 and Gpnmb that are derived from strain C57BL/6J (B6). These mice do not develop any iris disease, IOP elevation or glaucoma. DBA/2J-Gpnmb+/Sj mice (hereafter referred to as D2-Gpnmb+) are homozygous for a wild-type allele of Gpnmb on a D2 genetic background. This Gpnmb+ allele is the original D2 allele that predates the R150X mutation (See Methods). These mice develop a very mild form of iris disease due to the Tyrp1 b mutation, but do not develop elevated IOP or glaucoma. These strains further define the relative contributions of the Tyrp1 and Gpnmb genes to the D2 phenotype and will serve as powerful control strains in future studies of glaucoma.
D2.Tyrp1 B6 Gpnmb B6 show no iris disease, IOP elevation or glaucoma
As previously reported, the irides of D2 mice with both the Gpnmb R150X and Tyrp1 b mutations develop severe pigment dispersion and iris atrophy (Figure 2a–c). However, as expected, the irides of D2.Tyrp1 B6 Gpnmb B6 mice appear totally normal at all ages. IOP elevation is a key risk factor for glaucoma and occurs in D2 mice as a result of the iris disease. Typically, a population of D2 mice shows elevated IOP levels that peak at around 9–10 months of age (Figure 3a). In contrast, IOPs of D2.Tyrp1 B6 Gpnmb B6 mice are not elevated compared to young mice at any assessed age (Figure 3b).
D2.Tyrp1 B6 Gpnmb B6 mice have B6-derived chromosomal regions (congenic intervals) flanking Tyrp1 and Gpnmb respectively. Together, these B6-derived regions represent up to 3.3% of the genome (Figure 1). To produce an even more closely matched control strain, we developed D2-Gpnmb+, a second control strain that has no B6-derived congenic intervals. To generate the D2-Gpnmb+ strain, the Gpnmb R150X allele of modern day D2 mice was replaced with the Gpnmb+ allele from the D2-sdy strain (the original wild-type D2 Gpnmb allele, see Methods).
D2-Gpnmb+ mice develop a mild iris disease
D2-Gpnmb+ mice do not develop elevated IOP or glaucoma
DBA/2J is an established mouse model for inherited glaucoma that shows iris pigment dispersion, IOP elevation and optic nerve degeneration. D2 mice are homozygous for both the Gpnmb R150X and Tyrp1b mutations. Both of these mutations are necessary for the severe iris pigment disease that leads to IOP elevation and glaucoma . Although DBA/2J is an experimentally tractable model of glaucoma, it is an inbred mouse strain and so no strain matched DBA/2J controls without glaucoma have been available. Here we describe the generation of two derivative strains of DBA/2J (D2.Tyrp1 B6 Gpnmb B6 and D2-Gpnmb+), where either the mutant alleles of both Gpnmb and Tyrp1 or only Gpnmb have been replaced by wild-type versions. D2.Tyrp1 B6 Gpnmb B6 mice contain a maximum of 3.3% of B6-derived sequence on a D2 background. In the case of D2-Gpnmb+, the only known difference compared to D2 is a single base change in the Gpnmb gene. Neither D2.Tyrp1 B6 Gpnmb B6 nor D2-Gpnmb+ strains develop IOP elevation or glaucoma.
Since determining that the Gpnmb mutation recently arose on the DBA/2J background , we have produced a further control strain, D2.Tyrp1 B6 Gpnmb+, that is currently being characterized. This strain contains a congenic interval flanking Tyrp1 but is improved over D2.Tyrp1 B6 Gpnmb B6 in that it lacks a congenic interval around Gpnmb (as the Gpnmb+ allele is the ancestral DBA/2J allele). This strain is wild-type for both glaucoma inducing genes and is not expected to develop any D2 glaucoma-associated phenotypes. Although characterization of large numbers of these mice is a lengthy undertaking, initial analyses agree with the findings reported here for D2.Tyrp1 B6 Gpnmb B6 mice, with no evidence of iris disease, IOP elevation or glaucoma.
Regarding the control strains, the following points are pertinent. Although they lack all iris disease and glaucoma, the D2.Tyrp1 B6 Gpnmb B6 strain does not typically reproduce as well as the D2-Gpnmb+ strain and appears to have an increased incidence of early deaths (based on retrospective observations, but no specific spontaneous death study has been conducted). Although not well characterized, the decreased fecundity appears to be related to the Tyrp1B6 allele on a D2 background, since other D2 strains that we have been producing with this allele have exhibited a similar phenotype. These issues do not prevent the use of this strain. However, since the D2-Gpnmb+ strain lacks these issues and has no B6 derived interval, we recommend it as a control when studying glaucomatous neurodegeneration. Although the D2-Gpnmb+ strain still develops a mild iris disease, glaucomatous nerve damage was clearly absent in the vast majority, if not all, of these mice. Thus, despite the spread in IOP, the highest IOPs were not significant enough to induce glaucomatous axon loss. When using these control strains, it is important to remember that they may still have some undefined but glaucoma relevant phenotype(s).
It is clear that glaucoma is a multifactorial disease and D2 mice are likely to have susceptibility factors in addition to those associated with the Gpnmb and Tyrp1 genes. Thus, although these strains do not develop glaucoma, as defined by the absence of nerve damage, they may still have other phenotypes that render the D2 background susceptible to glaucoma. Such phenotypes may or may not have contributed to nerve the damage detected in a small percentage of mice.
Tyrp1 and Gpnmb function in melanosomes, organelles that produce pigment. Manifestation of both IPD and ISA in D2 eyes is dependent upon active pigment production [16, 20]. The mechanisms involved in IPD and ISA and the subsequent IOP elevation are complex and in addition to pigment production appear to involve immunity [21, 22]. Ongoing functional mouse genetics experiments complemented with a variety of immunological, molecular and cellular techniques are vital to unravel these mechanisms. The control strains described here will be a valuable resource in elucidating the biological mechanisms involved in pigment-related iris disease. In addition to ocular-related diseases, these strains provide an important resource to test the roles of Tyrp1 and Gpnmb in other diseases. Tyrp1 is the most common melanoma antigen and Gpnmb is used as a marker for metastatic melanomas  and has recently been identified as a potential molecular therapeutic target in patients with glioblastoma multiforme . Gpnmb may also be important in antigen presenting cells that control immune responses .
To improve our understanding of glaucoma, it is essential that genes and pathways involved in IOP elevation and glaucomatous RGC and optic nerve degeneration are identified. By analyzing gene expression profiles in D2 mice at various ages , and conducting subsequent functional tests, it is possible to identify differentially expressed genes important for the onset and/or progression of glaucoma. Individual mouse strains, such as D2, have a unique collection of alleles affecting many biological processes and that affect gene expression levels and protein activity . Therefore, many gene expression differences are observed between D2 and other naturally occurring strains that do not get glaucoma . This can complicate experiments and make it difficult to prioritize genes for subsequent functional testing. Additionally, it is possible that strain differences can mask some expression changes that occur in D2 mice and are relevant to the glaucoma. By enabling analysis of age- and strain-matched control mice, the control strains reported here alleviate the difficulties of controlling experiments using D2 mice.
The strains describes here will enable the systematic evaluation of the processes involved in iris disease, IOP elevation and glaucoma, work that is likely to provide novel understanding and lead to targets for improved therapeutics for human glaucomas.
Animal husbandry and strain development
Mice were housed in a 14 h light to 10 h dark cycle under previously described conditions [9, 15]. The Jackson Laboratory's (Bar Harbor, Maine, United States) pathogen surveillance program regularly screened for pathogens. All experiments were conducted in accordance with the Association for Research in Vision and Ophthalmology's statement on the use of animals in ophthalmic research and were approved by our institutional animal care and use committee. Modern DBA/2J (D2) mice (#000671, see ) have mutations in both Tyrp1 and Gpnmb. Although the majority of included data for modern D2 mice has been previously published, over 300 modern D2 mice were aged and analyzed over the same period of time as the mice of the other strains presented here. For the generation of the D2.Tyrp1 B6 Gpnmb B6 strain, D2 mice were crossed to C57BL/6J (B6) to create F1s. Progeny carrying the B6 allele of both Gpnmb (Gpnmb B6 ) and Tyrp1 (Tyrp1 B6 ) were then backcrossed to D2 for ten generations. Brother/sister matings were then established to generate mice homozygous for Gpnmb B6 and Tyrp1 B6 and to maintain a stable D2.Tyrp1 B6 Gpnmb B6 doubly homozygous colony.
The Gpnmb R150X mutation arose in the early 1980s and became fixed in the ancestors of modern day D2 mice . The sdy mutation alters coat color and occurred in DBA/2J (D2) mice in 1983. At that point, the DBA/2J-Dtnbp1 sdy strain (hereafter referred to as D2-sdy) was separated from the main D2 colony. Genotyping a D2-sdy colony for Gpnmb in the early 2000s revealed that these mice had an original wild-type allele of Gpnmb (Gpnmb+). To develop the D2-Gpnmb+ strain, D2-sdy were crossed to modern D2 mice for three generations. We are continuing to backcross D2-Gpnmb+ to modern day D2 to further reduce the possibility of D2-Gpnmb+ mice harboring unknown genetic differences compared to modern day D2 mice. These higher generation D2-Gpnmb+ mice will be provided to the community. (They are being accepted for distribution by Jackson Laboratory mouse resources and will become strain DBA/2J-Gpnmb+/SjJ with stock # 007048). However, to hasten characterization of mice with a D2 genetic background and a wild type allele of Gpnmb, brother/sister matings that did not carry the sdy mutation were selected to establish the D2-Gpnmb+ strain that is homozygous for the wild-type Gpnmb allele and characterized here. These matings also produced the mice for clinical examinations, IOP measurements and assessment of glaucomatous damage. Analysis of 102 microsatellite markers (average spacing 13.25 cM) revealed no allelic differences between D2-Gpnmb+ and modern day D2.
The Gpnmb R150X mutation creates a novel Pvu II enzyme site . DNA isolated from tail snips was used to PCR amplify the 125 bp region surrounding the mutation using primers nmb7 (CTACAACTGGACTGCAGGGG) and nmb8 (AGCTCCATTTCTTCCATCCA). The resulting product was digested with Pvu II (NEB). The presence of the mutation is indicated by the presence of two bands of 50 bp and 75 bp. Identification of B6-derived sequence that included Tyrp1 on Chromosome 4 was achieved using the flanking polymorphic markers D4Mit178 (D2 = 170 bp, B6 = 146 bp) and D4Mit327 (D2 = 92 bp, B6 = 106 bp). Identification of B6-derived sequence that included Gpnmb on Chromosome 6 was achieved using the flanking polymorphic markers D6Mit74 (D2 = 150 bp, B6 = 160 bp) and D6Mit355 (D2 = 106 bp, B6 = 124 bp). The extent of the B6-derived region was analyzed using polymorphic markers spanning Chromosomes 4 and 6 (see ).
We examined eyes at 2–24 months of age with a slit-lamp biomicroscope (Haag-Streit) and photographed them with a 40× objective lens. Phenotypic assessment of iris stromal atrophy, dispersed pigment and transillumination was carried out as described previously [9, 15, 20].
IOP and optic nerve assessment
Mice were acclimatized to the procedure room, anesthetized by using an intraperitoneal injection of ketamine/xylazine mixture and IOP measured as previously described . Optic nerve cross sections were examined for glaucomatous damage using a modified paraphenylenediamine (PPD) staining protocol to stain the myelin sheath of all axons and the axoplasma of damaged axons as described previously . Optic nerves were assessed for glaucomatous damage using a non-biased three point grading system that has been validated against axon counting [18, 19]. Axon counts were carried out as previously described [18, 19]. 10 randomly selected D2 eyes (pre-glaucomatous, 3 to 4 months) and 10 randomly selected D2-Gpnmb+ eyes (no glaucoma, 10.5 to 11 mos) were counted.
Eyes were fixed in 4% paraformaldehyde (PFA) overnight at 4°C and stored in 0.4% PFA at 4°C. For general morphology, eyes were processed, embedded in plastic, sectioned and stained with Hemotoxylin and Eosin.
The authors thank Amy Snow for strain development and maintenance, and IOP measurements. We thank Greg Peterson and the John Lab for technical assistance. We also thank The Jackson Laboratory Scientific Services including Pete Finger and Barbara Mortimer for technical assistance. Scientific support services at The Jackson Laboratory are subsidized by a core grant from the National Cancer Institute (CA34196). This work was supported in part by the National Eye institute, EY11721 (S.W.M.J), F32EY014515 (R.T.L.) and F32EY07015 (M.G.A.). S.W.M. John is an Investigator of The Howard Hughes Medical Institute.
- Quigley HA: Number of people with glaucoma worldwide. The British journal of ophthalmology. 1996, 80 (5): 389-393.PubMed CentralView ArticlePubMed
- Hitchings RA: Glaucoma – Fundamentals of Clinical Ophthalmology. 2000, London: BMJ Publishing Group
- Ritch R, Shields MB, Krupin T: The Glaucomas: Clinical Science. 1996, St Louis, MO: Mosby-Year Book, 2
- Palmberg PF, Wiggs JL: Mechanisms of Glaucoma. Ophthalmology. Edited by: Yanoff M, Duker JS. 2004, St Louis, MO.: Mosby, 2
- Lutjen-Drecoll E, Rohen JW: Morphology of aqueous outflow pathways in normal and glaucomatous eyes. The Glaucomas. Edited by: Ritch R, Shields MB, Krupin T. 1996, St Louis, MO: Mosby-Year Book, 89-123.
- Campbell DG, Schertzer RM: Pigmentary Glaucoma. The Glaucomas. Edited by: Ritch R, Shields MB, Krupin T. 1996, St Louis: Mosby, 975-991.
- Ritch R: A unification hypothesis of pigment dispersion syndrome. Transactions of the American Ophthalmological Society. 1996, 94: 381-405. discussion 405-389.PubMed CentralPubMed
- Shields MB: Glaucomas associated with disorders of the iris. Textbook of Glaucoma. 1992, Baltimore: Williams and Wilkins, 276-286. 4
- John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D, Davisson M, Roderick TH, Heckenlively JR: Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Investigative ophthalmology & visual science. 1998, 39 (6): 951-962.
- Libby RT, Anderson MG, Pang IH, Robinson ZH, Savinova OV, Cosma IM, Snow A, Wilson LA, Smith RS, Clark AF, et al: Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. Vis Neurosci. 2005, 22 (5): 637-648.View ArticlePubMed
- Libby RT, Gould DB, Anderson MG, John SW: Complex genetics of glaucoma susceptibility. Annu Rev Genomics Hum Genet. 2005, 6: 15-44. 10.1146/annurev.genom.6.080604.162209.View ArticlePubMed
- Danias J, Lee KC, Zamora MF, Chen B, Shen F, Filippopoulos T, Su Y, Goldblum D, Podos SM, Mittag T: Quantitative analysis of retinal ganglion cell (RGC) loss in aging DBA/2NNia glaucomatous mice: comparison with RGC loss in aging C57/BL6 mice. Investigative ophthalmology & visual science. 2003, 44 (12): 5151-5162. 10.1167/iovs.02-1101.View Article
- Schlamp CL, Li Y, Dietz JA, Janssen KT, Nickells RW: Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC neuroscience. 2006, 7: 66-10.1186/1471-2202-7-66.PubMed CentralView ArticlePubMed
- Schuettauf F, Rejdak R, Walski M, Frontczak-Baniewicz M, Voelker M, Blatsios G, Shinoda K, Zagorski Z, Zrenner E, Grieb P: Retinal neurodegeneration in the DBA/2J mouse-a model for ocular hypertension. Acta neuropathologica. 2004, 107 (4): 352-358. 10.1007/s00401-003-0816-9.View ArticlePubMed
- Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova O, Roderick TH, Heckenlively JR, Davisson MT, John SW: Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nature genetics. 1999, 21 (4): 405-409. 10.1038/7741.View ArticlePubMed
- Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW: Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nature genetics. 2002, 30 (1): 81-85. 10.1038/ng794.View ArticlePubMed
- Zdarsky E, Favor J, Jackson IJ: The molecular basis of brown, an old mouse mutation, and of an induced revertant to wild type. Genetics. 1990, 126 (2): 443-449.PubMed CentralPubMed
- Anderson MG, Libby RT, Gould DB, Smith RS, John SW: High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102 (12): 4566-4571. 10.1073/pnas.0407357102.PubMed CentralView ArticlePubMed
- Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, John SW: Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005, 1 (1): 17-26. 10.1371/journal.pgen.0010004.View ArticlePubMed
- Anderson MG, Libby RT, Mao M, Cosma IM, Wilson LA, Smith RS, John SW: Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC biology. 2006, 4: 20-10.1186/1741-7007-4-20.PubMed CentralView ArticlePubMed
- Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW: By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med. 2003, 197 (10): 1335-1344. 10.1084/jem.20022041.PubMed CentralView ArticlePubMed
- Zhou X, Li F, Kong L, Tomita H, Li C, Cao W: Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma. The Journal of biological chemistry. 2005, 280 (35): 31240-31248. 10.1074/jbc.M502641200.View ArticlePubMed
- Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP: nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. International journal of cancer. 1995, 60 (1): 73-81. 10.1002/ijc.2910600111.View Article
- Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006, 12 (7 Pt 1): 1970-1982. 10.1158/1078-0432.CCR-05-2797.View ArticlePubMed
- Steele MR, Inman DM, Calkins DJ, Horner PJ, Vetter ML: Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma. Investigative ophthalmology & visual science. 2006, 47 (3): 977-985. 10.1167/iovs.05-0865.View Article
- Wade CM, Daly MJ: Genetic variation in laboratory mice. Nature genetics. 2005, 37 (11): 1175-1180. 10.1038/ng1666.View ArticlePubMed
- Nadler JJ, Zou F, Huang H, Moy SS, Lauder J, Crawley JN, Threadgill DW, Wright FA, Magnuson TR: Large-scale gene expression differences across brain regions and inbred strains correlate with a behavioral phenotype. Genetics. 2006, 174 (3): 1229-1236. 10.1534/genetics.106.061481.PubMed CentralView ArticlePubMed
- Jaxmice. [http://jaxmice.jax.org]
- Mouse Genome Informatics. [http://www.informatics.jax.org]
- Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS, John SW: Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet. 2001, 2: 12-10.1186/1471-2156-2-12.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.